Peptide research, explained.
Detailed guides to peptide identity, biological pathways, analytical methods and clinical evidence. Search the reading room or follow a research topic.
Browse 13 research topics
All guides & articles
Peptide FundamentalsPRRT Half-Life: What It Means in Peptide Receptor Therapy
In peptide receptor radionuclide therapy (PRRT), half-life can describe radioactive decay, biological clearance or both. Learn how those meanings differ.
Updated 2026-11-05 ↗
Research PracticePeptides for Hair Growth: Follicle Models vs Human Outcomes
A hair follicle growing in an ex vivo experiment is not the same outcome as improved scalp hair density in a controlled human study.
Updated 2026-10-29 ↗
Research PracticePeptides for Muscle Growth: What the Evidence Measures
Peptides for muscle growth are often discussed through hormone responses or increases in lean mass. Neither is the same as measured muscle strength or physical function.
Updated 2026-10-29 ↗
Research PracticePetrelintide: Reading the New Amylin Research
Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.
Updated 2026-10-29 ↗
Peptide FundamentalsPramlintide: Understanding Amylin Beyond the GLP-1 Headlines
Pramlintide is an amylin analogue with a product-specific role alongside mealtime insulin. Its evidence should not be read as a generic weight-loss-peptide comparison.
Updated 2026-10-29 ↗
Research PracticeRetatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons
Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.
Updated 2026-10-29 ↗
Research PracticeSemaglutide and Alcohol Craving: The Trials Do Not All Say the Same Thing
Semaglutide alcohol-use research contains promising findings and results that resist a simple headline.
Updated 2026-10-29 ↗
Research PracticeSemaglutide and Diabetic Retinopathy: Reading the Safety Signal
The semaglutide retinopathy signal arose from a defined complication endpoint in SUSTAIN 6, a cardiovascular trial involving people with type 2 diabetes at high cardiovascular risk.
Updated 2026-10-29 ↗
Research PracticeSemaglutide and Kidney Disease: What the FLOW Trial Found
FLOW studied adults with type 2 diabetes and chronic kidney disease. Its 24% lower hazard concerned a composite of major kidney events and kidney-related or cardiovascular death.
Updated 2026-11-15 ↗
Research PracticeSemaglutide and Heart Outcomes: The SELECT Population Matters
SELECT tested a cardiovascular question in adults with established cardiovascular disease and overweight or obesity, without diabetes.
Updated 2026-10-29 ↗
Research PracticeSemaglutide vs Tirzepatide: What Head-to-Head Evidence Shows
SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.
Updated 2026-10-29 ↗
Research PracticeSemaglutide Weight Loss Plateau: What the Trials Show
In STEP 5, average semaglutide weight loss leveled off around week 60 and was maintained through week 104. A plateau does not by itself mean treatment has stopped working.
Updated 2026-11-15 ↗